Sath Shukla - Feb 1, 2024 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
CEO and President, Director
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Sath Shukla
Stock symbol
SPRO
Transactions as of
Feb 1, 2024
Transactions value $
-$107,719
Form type
4
Date filed
2/5/2024, 08:40 PM
Previous filing
Aug 30, 2023
Next filing
Aug 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +680K +118.69% $0.00 1.25M Feb 1, 2024 Direct F1
transaction SPRO Common Stock Sale -$42.3K -30.9K -2.47% $1.37 1.22M Feb 2, 2024 Direct F2, F3
transaction SPRO Common Stock Sale -$65.4K -45.1K -3.69% $1.45 1.18M Feb 5, 2024 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
F2 The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement.
F3 Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4 The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023.